Suppr超能文献

帕金森病中的大麻 - 从患者角度与临床试验对比:系统文献回顾。

Cannabis in Parkinson's Disease - the patient's perspective versus clinical trials: a systematic literature review.

机构信息

Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland.

Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland.

出版信息

Neurol Neurochir Pol. 2022;56(1):21-27. doi: 10.5603/PJNNS.a2022.0004. Epub 2022 Jan 5.

Abstract

Cannabis and cannabinoids are often considered in the treatment of Parkinson's Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.

摘要

大麻和大麻素常被用于治疗帕金森病(PD)。本文旨在对大麻治疗的现有数据进行系统评价。我们旨在评估随机试验以及患者调查。我们共发现了 569 篇关于 PD 和大麻素治疗的论文。其中,仅有 7 篇论文涉及不同大麻素对 PD 运动症状影响的随机试验。这些试验的结果并不支持大麻素治疗 PD 运动症状的疗效。基于现有数据,我们得出结论,目前尚无足够数据支持向 PD 患者给予大麻素。应开展更大规模、随机的 PD 大麻使用研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验